A Comparative Study to Evaluate Health Outcomes Regarding The Effect of Rosacea on Eye Health in Iraqi Patients
Abstract
Rosacea is a chronic inflammatory skin condition that frequently presents with ocular symptoms, yet its impact on eye health remains underrecognized in clinical settings. The link between dermatological and ocular manifestations is often overlooked, leading to delayed diagnosis and suboptimal management. This study addresses this gap by conducting a cross-sectional observational comparison of ocular health outcomes in 160 Iraqi adults—120 with rosacea and 40 healthy controls. Standardized questionnaires (DLQI and OSDI), clinical ophthalmologic assessments, and oxidative stress biomarker analyses were employed. The findings reveal significantly higher rates of ocular comorbidities, including blepharitis (55% vs 25%, aOR = 6.50, p<0.001), dry eye syndrome, and conjunctivitis in rosacea patients. Schirmer’s test and tear break-up time results were markedly lower among rosacea patients, indicating impaired tear film. Quality of life scores were significantly worse in the rosacea group. Additionally, oxidative stress markers (TOS, OSI) were elevated, while antioxidant levels (TAS, ARE) were reduced, suggesting a possible pathophysiological mechanism. The study concludes that ocular involvement in rosacea is clinically significant, requiring interdisciplinary awareness and management. Early screening for ocular symptoms and integration of dermatological and ophthalmological care can improve patient outcomes and prevent vision-threatening complications.
References
M. Steinhoff, J. Schauber, and J. J. Leyden, “New insights into rosacea pathophysiology: a review of recent findings,” J. Am. Acad. Dermatol., vol. 69, pp. 15–26, 2013, doi: 10.1016/j.jaad.2013.04.045
A. C. Vieira, A. L. Höfling-Lima, and M. J. Mannis, “Ocular rosacea: a review,” Arq. Bras. Oftalmol., vol. 75, no. 5, pp. 363–369, 2012, doi: 10.1590/s0004-27492012000500016.
J. L. Michel and F. Cabibel, “Frequency, severity, and treatment of ocular rosacea during cutaneous rosacea,” Ann. Dermatol. Venereol., vol. 130, no. 1, pp. 20–24, 2003.
J. Wilkin et al., “Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea,” J. Am. Acad. Dermatol., vol. 50, no. 6, pp. 907–912, 2004, doi: 10.1016/j.jaad.2004.01.048.
A. S. Eiseman, “The ocular manifestations of atopic dermatitis and rosacea,” Curr. Allergy Asthma Rep., vol. 6, no. 4, pp. 292–298, 2006, doi: 10.1007/s11882-006-0062-z.
M. Oltz and J. Check, “Rosacea and its ocular manifestations,” Optometry, vol. 82, no. 2, pp. 92–103, 2011, doi: 10.1016/j.optm.2010.01.015.
M. Heisig and A. Reich, “Psychosocial aspects of rosacea with a focus on anxiety and depression,” Clin. Cosmet. Investig. Dermatol., vol. 11, pp. 103–107, 2018.
J. Wilkin et al., “Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea,” J. Am. Acad. Dermatol., vol. 46, pp. 584–587, 2002.
R. S. Q. Geng, J. Slomovic, A. N. Bourkas et al., “Ocular rosacea: the often‐overlooked component of rosacea,” JEADV Clin. Pract., vol. 3, pp. 1349–1363, 2024.
N. V. Patel, N. Gupta, and R. Shetty, “Preferred practice patterns and review on rosacea,” Indian J. Ophthalmol., vol. 71, pp. 1382–1390, 2023.
J. Tan, U. Blume-Peytavi, J. P. Ortonne et al., “An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes,” Br. J. Dermatol., vol. 169, pp. 555–562, 2013
C. M. Longo, A. P. Adam, and E. J. Wladis, “Rosacea and the eye: a recent review,” Expert Rev. Ophthalmol., vol. 13, pp. 57–64, 2018.
M. M. D. Van der Linden, A. R. van Ratingen, D. C. van Rappard, S. A. Nieuwenburg, and P. I. Spuls, “DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial,” Br. J. Dermatol., vol. 176, pp. 1465–1474, 2017.
E. J. Van Zuuren, Z. Fedorowicz, B. Carter, M. M. Van der Linden, and L. Charland, “Interventions for rosacea,” Cochrane Database Syst. Rev., 2015, Art. no. CD003262.
M. M. Van der Linden et al., “Health-related quality of life in patients with cutaneous rosacea: a systematic review,” Acta Derm. Venereol., vol. 95, pp. 395–400, 2015
A. Liberati et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” J. Clin. Epidemiol., vol. 62, pp. e1–e34, 2009.
G. Wells et al., The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Ottawa: Hospital Research Institute, 2000.
J. P. Craig et al., “TFOS DEWS II definition and classification report,” Ocul. Surf., vol. 15, pp. 276–283, 2017.
A. J. Bron et al., “TFOS DEWS II pathophysiology report,” Ocul. Surf., vol. 15, pp. 438–510, 2017.
E. Muhafız, S. A. Bayhan, H. A. Bayhan, E. Çölgeçen, and C. Gürdal, “Evaluation of meibomian glands in cutaneous rosacea,” Med. J. SDU, vol. 28, pp. 621–626, 2021.
R. M. Schiffman et al., “Reliability and validity of the ocular surface disease index,” Arch. Ophthalmol., vol. 118, pp. 615–621, 2000.
I. M. Balmus, A. I. Alexa, R. E. Ciuntu et al., “Oxidative stress markers dynamics in keratoconus patients’ tears before and after the corneal collagen crosslinking procedure,” Exp. Eye Res., vol. 190, Art. no. 107897, 2020.
L. Haagen and A. Brock, “A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenylacetate,” Eur. J. Clin. Chem. Clin. Biochem., vol. 30, pp. 391–395, 1992.
D. Jones, “Reactive oxygen species and rosacea,” Cutis, vol. 74, no. 3 Suppl., pp. 17–20, 32–34, 2004.
Copyright (c) 2025 Dr. Omar Salim Mahmood
This work is licensed under a Creative Commons Attribution 4.0 International License.
